Furthermore, because KRAS variants and co-mutations are related to the efficacy of ICIs [106, 107], combinations of KRAS inhibitors and ICIs are also being investigated (Table 3). Some of these strategies may become upfront choices for advanced KRAS-driven NSCLC in the future. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.